Sight Sciences, Inc.

NASDAQ:SGHT

Medical - Devices

Healthcare
$10.77 +2.89%

+$0.15 today

Market cap
$598.59M
Beta
2.40
P/E (TTM)
-7.5
EPS (TTM)
-$0.69
52W Low $3.11High $9.24

Volume 0.34M

Average 0.25M

SGHT EBITDA Margin

EBITDA as a percentage of revenue.

Sight Sciences, Inc.NASDAQ: SGHT

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -58.9%

EBITDA Margin was -58.9% in Q1 FY2026, up 13.7 pp from a year earlier. On a trailing-twelve-month basis it was -39.8%, up 16.3 pp year over year. Over 3 fiscal years it widened by 70.4 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -25.2% for the fiscal year ending Dec 2026, up from -42.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-58.9%-45.4 pp QoQ
Last fiscal yearDec 2025
-42.4%+15.1 pp YoY
LTMMar 2026
-39.8%+16.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+13.7 pp+17.9 pp+4.2 pp
1 year+15.1 pp+17.2 pp+2.1 pp
3 years+70.4 pp+30.8 pp-39.6 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-42.4%
Year-over-year change
+15.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SGHT compares with its peers on the latest reported figures

  • SGHT's LTM Mar 2026 EBITDA Margin of -39.8% is the 5th highest of the 6 companies compared; the peer median is 11.7%.
  • Its year-over-year change of +16.3 pp is the highest of 6, against a peer median of -12.0 pp.
  • Over three fiscal years its change of +70.4 pp compares with a peer median of -4.5 pp.
SGHT Competitors Peer median
EBITDA Margin for SGHT and competitors
Company Period LTM level YoY 3-year change
ALCAlcon Inc.LTM Sep 202625.4% -0.9 pp+4.0 pp
BHCBausch Health Companies Inc.LTM Jun 202618.9% -14.3 pp-4.5 pp
HROWHarrow Health, Inc.LTM Mar 202611.7% +3.4 pp+19.6 pp
GKOSGlaukos CorporationLTM Jun 2026-23.0% -12.0 pp-11.5 pp
SGHTSight Sciences, Inc.LTM Mar 2026-39.8% +16.3 pp+70.4 pp
OCULOcular Therapeutix, Inc.LTM Mar 2026-527.0% -231.3 pp-361.8 pp
SGPSpyGlass Pharma, Inc. Common StockFY2025— ——
Peer median (excluding SGHT) 11.7%-12.0 pp-4.5 pp

Competitors are the stored peer set for SGHT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.96M71.33M81.06M79.87M77.36M
Cost of Revenue8.61M12.36M11.88M11.58M10.7M
Gross Profit40.35M58.97M69.18M68.29M66.67M
Gross Margin82.4%82.7%85.3%85.5%86.2%
Research & Development15.63M22.86M17.56M17.99M14.61M
Selling, General & Admin76.19M120.07M108.89M100.83M89.16M
Operating Expenses91.82M142.92M126.45M118.82M103.77M
Depreciation & Amortization1.2M1.25M614K712K487K
EBITDA(57.21M)(80.48M)(49.42M)(45.9M)(32.79M)
EBITDA Margin-116.8%-112.8%-61.0%-57.5%-42.4%
Operating Income(51.48M)(83.95M)(57.27M)(50.53M)(37.1M)
Operating Margin-105.2%-117.7%-70.7%-63.3%-48.0%
Interest Income00003.97M
Interest Expense4.37M4.47M5.41M4.66M5.14M
Other Income / Expenses(11.29M)(2.24M)1.84M(739K)(1.32M)
Income Before Tax(62.77M)(86.2M)(55.44M)(51.27M)(38.42M)
Pre-Tax Margin-128.2%-120.8%-68.4%-64.2%-49.7%
Income Tax Expense188K47K110K236K10K
Net Income(62.96M)(86.24M)(55.55M)(51.51M)(38.43M)
Net Margin-128.6%-120.9%-68.5%-64.5%-49.7%
EPS (Basic)(1.33)(1.80)(1.14)(1.03)(0.74)
EPS (Diluted)(1.33)(1.80)(1.14)(1.03)(0.74)
Weighted Avg Shares47.5M47.85M48.63M50.13M52.15M
Weighted Avg Shares (Diluted)47.5M47.85M48.63M50.13M52.15M

Sight Sciences, Inc.

NASDAQ:SGHT

Intrinsic Alpha fair value

Locked

Current Price

$10.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.